Thursday, November 16, 2006
Signature Mapping™ Represents the Application of Guardian’s Threat Detection Technology Applied to Healthcare Imaging
HERNDON, Va.--(BUSINESS WIRE)--Guardian Technologies International, Inc. (OTCBB:GDTI), a leading technology developer of intelligent imaging informatics (3i) solutions, today announced that it has successfully applied Guardian’s core digital imaging detection technology to medical images. “Our initial clinical results have clearly demonstrated that the application of our patented imaging analytics technology used for the detection of explosives, when applied to the analysis of medical images, will dramatically improve the diagnostic characteristics of digital medical images. We believe these advancements will result in improved and speedier diagnoses, and greater workflow efficiency for the diagnosing physician,” stated Guardian’s Vice President of Business Development, Richard Borrelli.
Guardian will demonstrate this innovative technology during the Radiology Society of North America (RSNA) conference held in Chicago in late November. RSNA provides the ideal platform for the introduction of this new technological breakthrough. RSNA is the largest radiographic conference in the world with an attendance of over 60,000 medical professionals, scientists and administrators. Guardian’s advanced research team has scheduled meetings with and will present to a prominent group of physicists, radiologists, researchers and practitioners from leading corporations and research universities in the healthcare imaging field.
Guardian will be demonstrating its clinical work with Signature Mapping™, a technology initially developed for threat detection, and currently under technical and scientific evaluation by governmental testing agencies in the United States and Russia. Signature Mapping™ is a unique methodology and algorithmic process that creates distinctive signature maps for organic or inorganic targeted materials. Signature Mapping™ is an adaptive, reaction-based analytical process whereby each image responds to applied algorithms. The resulting image signature map is then evaluated against a known library of targeted signature maps for the purpose of identification and characterization. The algorithmic process, built on machine learning platforms, can analyze and identify thousands of signature maps in real time.
Signature Mapping™ clinical results were derived from five pilot studies which have been conducted in a collaborative research and development effort with the Image Processing and Informatics Laboratory (IPI), University of Southern California (USC). The wide ranging clinical research includes detection and quantification of multiple sclerosis lesions; normal pressure hydrocephalus; acute intracranial hemorrhage; tuberculosis; and, the quantification, tracking, clarification, and detection in dense breast tissue.
Guardian Technologies International, Inc. (OTCBB:GDTI) is a pioneer in the development of new imaging techniques and applications. Guardian works to create new, innovative imaging technologies that result in the detection of threats and earlier detection of diseases, revolutionizing imaging processes and developing life-saving solutions.
For additional information, visit www.guardiantechintl.com.
This news release contains forward-looking statements that involve risks and uncertainties. Forward-looking statements in this document and those made from time to time by Guardian through its senior management are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the Company's current views with respect to the future events or financial performance discussed in this release, based on management's beliefs and assumptions and information currently available. When used, the words "believe", "anticipate", "estimate", "project", "should", "expect", "plan", "assume" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Forward-looking statements concerning future plans or results are necessarily only estimates and actual results could differ materially from expectations. Certain factors that could cause or contribute to such differences include, among other things, in particular, the size and timing of contract awards, performance on contracts, performance of acquired companies, availability and cost of key components, unanticipated results from audits of the financial results of the Company and acquired companies, changing interpretations of generally accepted accounting principles, outcomes of government reviews, developments with respect to litigation to which we are a party, potential fluctuations in quarterly results, dependence on large contracts and a limited number of customers, lengthy sales and implementation cycles, market acceptance of new or enhanced products and services, proprietary technology and changing competitive conditions, system performance, management of growth, dependence on key personnel, ability to obtain project financing, general economic and political conditions and other factors affecting spending by customers, the unpredictable nature of working with government agencies and other risks, uncertainties and factors including those described from time to time in Guardian's filings with the Securities and Exchange Commission, including without limitation, Guardian's Form 10-K for the year ended December 31, 2005 and its quarterly reports on Form 10-Q. Guardian expressly disclaims any obligation to update any forward-looking statements.